000 04283nam a22003855i 4500
001 281901
003 MX-SnUAN
005 20160429154125.0
007 cr nn 008mamaa
008 150903s2006 ne | o |||| 0|eng d
020 _a9781402005701
_99781402005701
024 7 _a10.1007/1402005709
_2doi
035 _avtls000334058
039 9 _a201509030722
_bVLOAD
_c201404120640
_dVLOAD
_c201404090420
_dVLOAD
_y201402041139
_zstaff
040 _aMX-SnUAN
_bspa
_cMX-SnUAN
_erda
050 4 _aQA276-280
100 1 _aCleophas, Ton J.
_eautor
_9308040
245 1 0 _aStatistics Applied to Clinical Trials /
_cby Ton J Cleophas, Aeilko H Zwinderman, Toine F Cleophas.
264 1 _aDordrecht :
_bSpringer Netherlands,
_c2006.
300 _axiii, 210 páginas
_brecurso en línea.
336 _atexto
_btxt
_2rdacontent
337 _acomputadora
_bc
_2rdamedia
338 _arecurso en línea
_bcr
_2rdacarrier
347 _aarchivo de texto
_bPDF
_2rda
500 _aSpringer eBooks
505 0 _aPreface -- Foreword -- 1. Hypotheses, Data, Stratification -- 2. The analysis of efficacy data of drug trials -- 3. The analysis of safety data of drug trials -- 4. Equivalence testing -- 5. Statistical power and sample size -- 6. Interim analysis -- 7. Multiple statistical inferences -- 8. Principles of linear regression -- 9. Subgroup analysis multiple linear regression: confounding, interaction, synergism -- 10. Curvilinear regression -- 11. Meta-analysis -- 12. Crossover studies with continuous variables: power analysis -- 13. Crossover studies with binary responses -- 14. Post-hoc analysis in clinical trials, a case for logistic regression analysis -- 15. quality-of-life assessment in clinical trials -- 16. Statistics for the analysis of genetic data -- 17. Relationship among statistical distributions -- 18. Statistics is not "bloodless" algebra -- Appendix -- Index.
520 _aIn 1948 the first randomized controlled trial was published by the English Medical Research Council in the British Medical Journal. Until then, observations had been uncontrolled. Initially, trials frequently did not confirm hypotheses to be tested. This phenomenon was attributed to low sensitivity due to small samples, as well as inappropriate hypotheses based on biased prior trials. Additional flaws were recognized and subsequently were better accounted for: carryover effects due to insufficient washout from previous treatments, time effects due to external factors and the natural history of the condition under study, bias due to asymmetry between treatment groups, lack of sensitivity due to a negative correlation between treatment responses, etc. Such flaws, mainly of a technical nature, have been largely corrected and led to trials after 1970 being of significantly better quality than before. The past decade has focused, in addition to technical aspects, on the need for circumspection in planning and conducting of clinical trials. As a consequence, prior to approval, clinical trial protocols are now routinely scrutinized by different circumstantial bodies, including ethics committees, institutional and federal review boards, national and international scientific organizations, and monitoring committees charged with conducting interim analyses. This book not only explains classical statistical analyses of clinical trials, but addresses relatively novel issues, including equivalence testing, interim analyses, sequential analyses, and meta-analyses, and provides a framework of the best statistical methods currently available for such purposes. The book is not only useful for investigators involved in the field of clinical trials, but also for all physicians who wish to better understand the data of trials as currently published.
590 _aPara consulta fuera de la UANL se requiere clave de acceso remoto.
700 1 _aZwinderman, Aeilko H.
_eautor
_9308041
700 1 _aCleophas, Toine F.
_eautor
_9308042
710 2 _aSpringerLink (Servicio en línea)
_9299170
776 0 8 _iEdición impresa:
_z9781402042294
856 4 0 _uhttp://remoto.dgb.uanl.mx/login?url=http://dx.doi.org/10.1007/1-4020-0570-9
_zConectar a Springer E-Books (Para consulta externa se requiere previa autentificación en Biblioteca Digital UANL)
942 _c14
999 _c281901
_d281901